Samsung Bioepis reviewing acquisition of Biogen’s biosimilar division
[이데일리 김진수 기자] Samsung Bioepis is preparing to acquire the biosimilar division of US pharmaceutical company Biogen. If the acquisition is successful, it is expected to secure global sales competitiveness following the development and production of biosimilars. Samsung Bioepis office building. (Photo = Samsung Bioepis) According to the industry on the 2nd, Samsung Bioepis was recently offered to acquire the biosimilar division from Biogen. Accordingly, a task force (TF) organization for the acquisition has been formed and review is underway. Biogen is known to be in contact with several acquisition candidates after being selected as the lead manager for the sale of the biosimilar division.
The industry is estimating the size of the acquisition at less than 1 trillion won, and if the acquisition is successful, it is expected that sales will increase by at least 400 billion won and profitability will also increase.
Samsung Bioepis has launched a total of seven biosimilars worldwide, including Benepali, Imraldi, Flixavi, an autoimmune disease treatment, and Bayoubiz, an eye disease treatment, and acquired Biogen’s biosimilar business. If so, sales growth and market share expansion are expected through the establishment of a global overseas direct sales (direct sales) system.
Biogen is a company in which Samsung Bioepis was established in 2012 as a joint venture and has been cooperating with the company for more than 10 years. Biogen’s biosimilar division consists of about 300 pharmaceutical sales experts in Europe and the US, and last year’s sales were 751 million dollars (approximately 960 billion won). Currently, biosimilar products developed by Samsung Bioepis are distributed in the global market.
After the recent failure to commercialize Alzheimer’s new drug ‘Arduhelm’, Biogen is undergoing restructuring by replacing its CEO and cutting 1,000 employees.
2023-08-02 01:45:30
#Samsung #Bioepis #reviewing #acquisition #Biogens #biosimilar #division
